Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Feb;107(3):267-9.
doi: 10.1172/JCI12094.

Mother-to-infant transmission of HIV-1: the placenta fights back

S A Spector  1
Affiliations

Mother-to-infant transmission of HIV-1: the placenta fights back

S A Spector. J Clin Invest. 2001 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mother-to-infant transmission of HIV-1. Increasing evidence indicates that transplacental transmission of HIV-1 is the result of a complex interaction between genetic factors of the virus, mother, and infant. Maternal high virus load and low CD4+ lymphocyte count are most often associated with transmission with CCR5-using virus (non–syncytium-inducing [NSI], macrophage-tropic), most often transmitted even when CXCR4-using virus (syncytium-inducing [SI], T cell–tropic) is present in the mother. Host genetic factors of mother and infant are also important determinants of transmission. Polymorphisms in genes encoding for the chemokine receptor CCR5 in the infant can decrease the risk of transmission. Also, polymorphisms in genes encoding for cytokines and hormones such as LIF, hCG, and IL-4 likely contribute to the placental barrier to viral transmission. Figure adapted in part from ref..
See this image and copyright information in PMC

Comment in

References

    1. Connor EM, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994; 331:1173–1180. - PubMed
    1. Wade NA, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998; 339:1409–1414. - PubMed
    1. Stiehm ER, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis. 1999; 179:567–575. - PubMed
    1. Lallemant M, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med. 2000; 343:982–991. - PubMed
    1. Guay LA, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999; 354:795–802. - PubMed

Publication types